163 related articles for article (PubMed ID: 38309417)
1. Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9.
Wang Y; Tinsley B; Spolitu S; Zadroga JA; Agarwal H; Sarecha AK; Ozcan L
J Lipid Res; 2024 Mar; 65(3):100515. PubMed ID: 38309417
[TBL] [Abstract][Full Text] [Related]
2. Geranylgeranyl Isoprenoids and Hepatic Rap1a Regulate Basal and Statin-Induced Expression of PCSK9.
Wang Y; Tinsley B; Spolitu S; Zadroga JA; Agarwal H; Sarecha AK; Ozcan L
bioRxiv; 2023 Oct; ():. PubMed ID: 37961667
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
Dong B; Singh AB; Shende VR; Liu J
Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
[TBL] [Abstract][Full Text] [Related]
7. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
[TBL] [Abstract][Full Text] [Related]
8. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PCSK9 by nutraceuticals.
Momtazi AA; Banach M; Pirro M; Katsiki N; Sahebkar A
Pharmacol Res; 2017 Jun; 120():157-169. PubMed ID: 28363723
[TBL] [Abstract][Full Text] [Related]
10. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
11. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.
Sliz E; Kettunen J; Holmes MV; Williams CO; Boachie C; Wang Q; Männikkö M; Sebert S; Walters R; Lin K; Millwood IY; Clarke R; Li L; Rankin N; Welsh P; Delles C; Jukema JW; Trompet S; Ford I; Perola M; Salomaa V; Järvelin MR; Chen Z; Lawlor DA; Ala-Korpela M; Danesh J; Davey Smith G; Sattar N; Butterworth A; Würtz P
Circulation; 2018 Nov; 138(22):2499-2512. PubMed ID: 30524137
[TBL] [Abstract][Full Text] [Related]
13. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
[TBL] [Abstract][Full Text] [Related]
14. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
[TBL] [Abstract][Full Text] [Related]
15. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
Kohli P; Desai NR; Giugliano RP; Kim JB; Somaratne R; Huang F; Knusel B; McDonald S; Abrahamsen T; Wasserman SM; Scott R; Sabatine MS
Clin Cardiol; 2012; 35(7):385-91. PubMed ID: 22714699
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of PCSK9 monoclonal antibodies.
Iqbal Z; Dhage S; Mohamad JB; Abdel-Razik A; Donn R; Malik R; Ho JH; Liu Y; Adam S; Isa B; Stefanutti C; Soran H
Expert Opin Drug Saf; 2019 Dec; 18(12):1191-1201. PubMed ID: 31623472
[No Abstract] [Full Text] [Related]
18. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
19. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
20. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
